替加环素治疗重症患者呼吸机相关性肺炎

doi:10.6040/j.issn.1671-7554.0.2016.692

山东大学学报（医学版） ›› 2017, Vol. 55 ›› Issue (4): 71-75.doi: 10.6040/j.issn.1671-7554.0.2016.692

替加环素治疗重症患者呼吸机相关性肺炎

孟伟¹,吴大玮¹,单悌超¹,张帆¹,郭海鹏¹,刘宇^1,2,丁士芳¹,翟茜¹

1.山东大学齐鲁医院重症医学科, 山东济南 250012;2.山东大学齐鲁医院感染管理处, 山东济南 250012

收稿日期:2016-06-10 出版日期:2017-04-10 发布日期:2017-04-10
通讯作者: 吴大玮. E-mail:wdw.55@163.com E-mail:wdw.55@163.com
基金资助:
卫生部国家临床重点专科建设项目(2011-873);中华医学会临床医学科研专项(1103016060)

Tigecycline in treating ventilator-associated pneumonia in critically ill patients

MENG Wei¹, WU Dawei¹, SHAN Tichao¹, ZHANG Fan¹, GUO Haipeng¹, LIU Yu^1,2, DING Shifang¹, ZHAI Qian¹

1. Intensive Care Unit, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
2. Infection Management Office, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China

Received:2016-06-10 Online:2017-04-10 Published:2017-04-10

摘要/Abstract

摘要： 目的评价替加环素治疗重症患者呼吸机相关性肺炎(VAP)的临床疗效与安全性。方法选取2011年1月1日至2013年5月31日山东大学齐鲁医院重症监护病房的VAP患者33例,给予替加环素治疗,初始剂量100 mg,维持剂量50 mg,静脉滴注,每隔12 h注射1次,根据患者具体病情确定给药疗程。评价患者的临床成功率、细菌清除率及安全性。结果入组病例37例,最终可评价病例33例,临床成功率61%(20/33)。共分离得到36株多重耐药菌,均对替加环素敏感,总清除率61%(22/36),其中分离率最高的鲍曼不动杆菌清除率60%(18/30)。不良反应以消化道症状为主,经临床对症治疗后好转。6例于治疗28 d内死亡。结论替加环素治疗危重患者VAP疗效确切,耐受性良好。

关键词: 替加环素, 多重耐药, 鲍曼不动杆菌, 危重症, 呼吸机相关性肺炎

Abstract: Objective To evaluate the clinical efficacy and safety of tigecycline in critically ill patients with ventilator-associated pneumonia(VAP). Methods A prospective study was conducted based on critically ill patients with VAP in Intensive Care Unit of Qilu Hospital of Shandong University during Jan 1, 2011 and May 31, 2013. All patients accepted intravenous infusion of tigecycline with a first dose of 100 mg and then 50 mg every 12 h. The course was directed by medical advice. The clinical and bacterial efficacy and safety were evaluated at the end of the therapy. Results A total of 37 patients were included at the beginning, and 33 patients were evaluable at the endpoint. The total clinical success rates was 60.6%. Thirty-six multidrug-resistance bacteria strains were detected in specimens obtained from all patients before the start of tigecycline treatment, and all these strains were sensitive to tigecycline. The total clearance rate was 61% while Acinetobacter baumannii predominated a 60% clearance rate. Adverse reactions were well tolerated with predominantly digestive symptoms, and all responded to symptomatic treatment afterwards. Six patients died within 28 days. Conclusion Tigecycline proved to be effective and safe for critically ill patients with VAP.

Key words: Tigecycline, Critical Illness, Drug Resistance, Multiple, Acinetobacter baumannii, Pneumonia, Ventilator-Associated

中图分类号:

R563.1

孟伟,吴大玮,单悌超,张帆,郭海鹏,刘宇,丁士芳,翟茜. 替加环素治疗重症患者呼吸机相关性肺炎[J]. 山东大学学报（医学版）, 2017, 55(4): 71-75.

MENG Wei, WU Dawei, SHAN Tichao, ZHANG Fan, GUO Haipeng, LIU Yu, DING Shifang, ZHAI Qian. Tigecycline in treating ventilator-associated pneumonia in critically ill patients[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(4): 71-75.

参考文献

[1] 管向东, 刘紫锰. 2013《呼吸机相关性肺炎诊断、预防和治疗指南》—目标性治疗的解读[J]. 中华医学杂志, 2014, 94(5): 333-334.
[2] 谭建龙, 张卫东, 柳威, 等. 替加环素治疗多或泛耐药鲍曼不动杆菌肺炎的疗效观察[J]. 中国呼吸与危重监护杂志, 2013, 12(6): 581-585. TAN Jianlong, ZHANG Weidong, LIU Wei, et al. Clinical experience with tigecycline in the treatment of multi/extensively drug-resistant acinetobacter baumannii pneumonia[J]. Chinese Journal of Respiratory and Critical Care Medicine, 2013, 12(6): 581-585.
[3] Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease[J]. Antimicrob Agents Chemother, 2011, 55(3): 1162-1172.
[4] Eckmann C, Heizmann WR, Leitner E, et al. Prospective, non-interventional, multi-centre trial of tigecycline in the treatment of severely ill patients with complicated infections: new insights into clinical results and treatment practice[J]. Chemotherapy, 2011, 57(4): 275-284.
[5] 中华医学会重症医学分会. 呼吸机相关性肺炎诊断、预防和治疗指南(2013)[J]. 中华内科杂志, 2013, 52(6): 524-543.
[6] 《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则[J]. 中国临床药理学杂志, 2014(9): 844-856.
[7] Bhavnani SM, Rubino CM, Hammel JP. et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline[J]. Antimicrob Agents Chemother, 2012, 56(2): 1065-1072.
[8] 朱任媛, 张小江, 杨启文, 等. 卫生部全国细菌耐药监测网2011年ICU来源细菌耐药监测[J]. 中国临床药理学杂志, 2012, 28(12): 905-909. ZHU Renyuan, ZHANG Xiaojiang, YANG Qiwen, et al. Ministry of health national antimicrobial resistance investigation net annual report of 2011: surveillance of antimicrobial resistance in bacteria from intensive care units[J]. The Chinese Journal of Clinical Pharmacology, 2012, 28(12): 905-909.
[9] Wu Yuhong, Shao Zonghong. High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia[J]. Chin Med J(Engl), 2014, 127(17): 3199.
[10] Ellis-Grosse EJ, Babinchak T, Dartois N, et al. Tigecycline 300 cSSSI study group; Tigecycline 305 cSSSI study group. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam[J]. Clin Infect Dis, 2005, 41(5): 341-353.
[11] Stein GE, Babinchak T. Tigecycline: an update[J]. Diagn Microbiol Infect Dis, 2013, 75(4): 331-336.
[12] Tanaseanu C, Bergallo C, Teglia O, et al. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia[J]. Diagn Microbiol Infect Dis, 2008, 61(3): 329-338.
[13] Moya Cordero P, Ruiz-Aragón J, Molina Linde JM, et al. Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections. Systematic review of literature[J]. Revista Chilena De Infectologia, 2013, 30(6): 591-597.
[14] Shin JA, Chang YS, Kim HJ, et al. Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection[J]. Yonsei Med, 2012, 53(5): 974-984.
[15] Montravers P, Dupont H, Bedos JP, et al. Tigecycline use in critically ill patients: a multicentre prospective observational study in the intensive care setting[J]. Intensive Care Med, 2014, 40(7): 988-997.
[16] Cai Y, Bai N, Liu X, et al. Tigecycline: Alone or in combination?[J]. Infect Dis(Lond), 2016, 48(7): 491-502.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed

替加环素治疗重症患者呼吸机相关性肺炎

Tigecycline in treating ventilator-associated pneumonia in critically ill patients

PDF (PC)

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

多维度评价

本文评价

推荐阅读 0

[1]	李安, 陈丰哲,王正,孟祥珠,许楠楠,马立宪. 西他沙星、头孢哌酮/舒巴坦和多黏菌素E单药及联合用药对泛耐药鲍曼不动杆菌的抗菌活性[J]. 山东大学学报（医学版）, 2017, 55(4): 82-85.
[2]	占明. 纤维支气管镜下肺泡灌洗在重症肺部感染治疗中的应用[J]. 山东大学学报（医学版）, 2014, 52(S2): 105-106.
[3]	叶瑞, 陈睿, 唐芳, 朱秋霞, 姜冬梅. 连续性肾脏替代治疗在60例危重症患者中的应用[J]. 山东大学学报（医学版）, 2014, 52(S2): 97-98.